Recruiting

New imaging scan to detect cancer spread in advanced breast cancer

Plain-English translation of NCT06611891 on ClinicalTrials.gov ↗ · Source last updated March 2025 · Translation generated August 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing a specialized imaging scan called PET to see if it can help doctors better detect where breast cancer has spread in the body. The scan uses a radioactive tracer to find cancer cells in patients with metastatic breast cancer — cancer that has already spread beyond the breast. Researchers want to understand whether this imaging method can provide useful information that standard scans may miss.

Currently, doctors use standard imaging scans to find where advanced breast cancer has spread, but these scans may not catch all the cancer in the body. This study explores whether the new imaging method could help doctors see the cancer more clearly and improve how they plan treatment.

Do you qualify?

You likely qualify if…

you are 18 years or older
you have been diagnosed with metastatic breast cancer (cancer that has spread to other parts of your body)
you have already completed at least one round of chemotherapy or other cancer treatment for your metastatic disease
your original breast cancer was hormone receptor positive and HER2 negative (a common type of breast cancer)
you have had a standard imaging scan within the past 21 days showing cancer in your liver and bones with at least 10 visible tumors

You likely don't qualify if…

you have or have had any other type of active cancer or neuroendocrine tumor
you have a known allergy to the imaging agent or its ingredients
you are unable or unwilling to provide written consent to participate
you have been enrolled in another clinical trial recently
you have received a new cancer treatment between your last standard scan and when you would receive this new scan

What participation looks like

If you join this study, you will come to the hospital for one visit where you will receive the specialized imaging scan called PET. The scan itself takes a few hours and involves receiving an injection of a radioactive tracer that helps the camera see cancer cells, followed by the imaging procedure. You will have a follow-up visit the same day to make sure you are doing well. The entire study takes place over a few weeks from your initial screening to final visit.

AI-generated summary from trial data · Aug 11, 2026 · Not medical advice

Trial locations(1 site)

France

CHU Grenoble Alpes, Grenoble